share_log

NOV Analyst Ratings

Benzinga ·  Oct 17, 2023 10:28
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
10/17/2023 25.57% Morgan Stanley $24 → $25 Maintains Overweight
10/03/2023 5.47% Wells Fargo $20 → $21 Maintains Equal-Weight
08/09/2023 -9.59% Goldman Sachs $16 → $18 Maintains Sell
08/01/2023 20.54% Morgan Stanley $22 → $24 Maintains Overweight
08/01/2023 30.59% Citigroup $21 → $26 Maintains Buy
07/31/2023 0.45% Piper Sandler $21 → $20 Maintains Neutral
07/31/2023 20.54% Morgan Stanley $22 → $24 Maintains Overweight
07/31/2023 40.63% Benchmark → $28 Reiterates Buy → Buy
07/31/2023 30.59% Citigroup $21 → $26 Maintains Buy
07/31/2023 40.63% Raymond James $27 → $28 Maintains Outperform
07/28/2023 0.45% Wells Fargo $18 → $20 Maintains Equal-Weight
07/18/2023 5.47% Citigroup $22 → $21 Maintains Buy
07/17/2023 10.5% Morgan Stanley $22 → $22 Reiterates Overweight → Overweight
07/14/2023 0.45% Capital One → $20 Initiates Coverage On → Equal-Weight
07/14/2023 35.61% Raymond James $29 → $27 Maintains Outperform
06/13/2023 -19.64% Goldman Sachs $17 → $16 Maintains Sell
06/02/2023 10.5% Citigroup $23 → $22 Maintains Buy
05/01/2023 5.47% Piper Sandler $22 → $21 Maintains Neutral
05/01/2023 0.45% Barclays $25 → $20 Maintains Equal-Weight
04/18/2023 10.5% Morgan Stanley $24 → $22 Maintains Overweight
04/05/2023 15.52% Citigroup $25 → $23 Maintains Buy
02/08/2023 35.61% Cowen & Co. $26 → $27 Maintains Outperform
02/08/2023 45.66% Susquehanna $26 → $29 Maintains Positive
02/08/2023 10.5% Piper Sandler → $22 Maintains Neutral
02/08/2023 35.61% RBC Capital → $27 Reiterates → Sector Perform
01/19/2023 40.63% Benchmark → $28 Initiates Coverage On → Buy
01/04/2023 20.54% Morgan Stanley $21 → $24 Upgrades Equal-Weight → Overweight
11/07/2022 25.57% Wells Fargo $16 → $25 Upgrades Underweight → Equal-Weight
11/01/2022 25.57% Barclays $22 → $25 Maintains Equal-Weight
10/31/2022 5.47% Morgan Stanley $20 → $21 Maintains Equal-Weight
10/13/2022 0.45% Morgan Stanley $19 → $20 Maintains Equal-Weight
10/12/2022 25.57% Citigroup → $25 Upgrades Neutral → Buy
09/30/2022 -4.57% B of A Securities → $19 Upgrades Neutral → Buy
08/25/2022 Benchmark Initiates Coverage On → Hold
07/29/2022 -4.57% Morgan Stanley $18 → $19 Maintains Equal-Weight
07/29/2022 B of A Securities Upgrades Underperform → Neutral
07/13/2022 -9.59% Morgan Stanley $20 → $18 Maintains Equal-Weight
07/13/2022 -19.64% Goldman Sachs $18 → $16 Maintains Sell
06/08/2022 10.5% Barclays $20 → $22 Maintains Equal-Weight
05/02/2022 0.45% Barclays $15 → $20 Maintains Equal-Weight
04/11/2022 0.45% Morgan Stanley $17 → $20 Maintains Equal-Weight
03/31/2022 -19.64% Wells Fargo $14 → $16 Maintains Underweight
02/23/2022 -19.64% Goldman Sachs → $16 Downgrades Neutral → Sell
02/07/2022 JP Morgan Downgrades Overweight → Neutral
12/14/2021 -14.62% JP Morgan → $17 Upgrades Neutral → Overweight
10/11/2021 -14.62% Morgan Stanley $18 → $17 Maintains Equal-Weight
09/09/2021 -24.66% RBC Capital → $15 Assumes → Sector Perform
07/19/2021 -24.66% BMO Capital $14 → $15 Upgrades Underperform → Market Perform
07/16/2021 B of A Securities Upgrades Neutral → Buy
07/09/2021 -9.59% Morgan Stanley $13 → $18 Upgrades Underweight → Equal-Weight
05/13/2021 -9.59% Goldman Sachs → $18 Initiates Coverage On → Neutral
04/29/2021 -34.71% Morgan Stanley $12 → $13 Maintains Underweight
01/21/2021 -14.62% Wells Fargo $13.5 → $17 Upgrades Equal-Weight → Overweight
01/12/2021 -9.59% Citigroup $15 → $18 Upgrades Neutral → Buy
01/06/2021 B of A Securities Upgrades Underperform → Neutral
11/10/2020 Morgan Stanley Downgrades Equal-Weight → Underweight
10/28/2020 -39.73% Wells Fargo $13.5 → $12 Maintains Equal-Weight
10/28/2020 -24.66% Stifel $16 → $15 Maintains Buy
10/28/2020 -24.66% Credit Suisse $14 → $15 Reiterates → Outperform
10/02/2020 -54.8% BMO Capital → $9 Initiates Coverage On → Underperform
07/29/2020 -24.66% JP Morgan $14 → $15 Maintains Neutral
07/29/2020 -43.24% Piper Sandler $11.4 → $11.3 Maintains Neutral
07/09/2020 -34.71% Morgan Stanley $12 → $13 Maintains Equal-Weight
05/26/2020 -44.75% UBS $10 → $11 Maintains Neutral
05/14/2020 -59.82% Barclays → $8 Downgrades Overweight → Equal-Weight
04/29/2020 -19.64% Stifel $18 → $16 Maintains Buy
04/29/2020 -54.8% Piper Sandler $11 → $9 Maintains Neutral
04/29/2020 -29.68% Raymond James $11 → $14 Maintains Outperform
04/14/2020 -14.62% Cowen & Co. → $17 Upgrades Market Perform → Outperform
04/09/2020 -49.77% UBS $21 → $10 Maintains Neutral
04/01/2020 -9.59% Stifel $17 → $18 Maintains Buy
03/27/2020 -34.71% RF Lafferty $27 → $13 Maintains Buy
03/27/2020 -44.75% Piper Sandler → $11 Downgrades Overweight → Neutral
03/20/2020 -34.71% Credit Suisse $25 → $13 Upgrades Neutral → Outperform
03/19/2020 -29.68% Barclays $25 → $14 Upgrades Equal-Weight → Overweight
03/10/2020 -14.62% Stifel $28 → $17 Maintains Buy
03/03/2020 5.47% UBS $25 → $21 Maintains Neutral
02/19/2020 Argus Research Downgrades Buy → Hold
02/10/2020 30.59% Wells Fargo $25 → $26 Maintains Equal-Weight
02/10/2020 50.68% Susquehanna $28 → $30 Maintains Positive
02/10/2020 35.61% Cowen & Co. $25 → $27 Maintains Market Perform
01/14/2020 Bernstein Initiates Coverage On → Market Perform
01/09/2020 25.57% Wells Fargo $24 → $25 Maintains Equal-Weight
12/10/2019 40.63% Citigroup $27 → $28 Maintains Buy
10/30/2019 65.75% Goldman Sachs $29 → $33 Upgrades Neutral → Buy
10/08/2019 25.57% Morgan Stanley $28 → $25 Maintains Equal-Weight
10/01/2019 35.61% Citigroup $28 → $27 Maintains Buy
09/12/2019 20.54% Wells Fargo $22 → $24 Maintains Market Perform
09/05/2019 25.57% Jefferies $23 → $25 Upgrades Hold → Buy
08/29/2019 Johnson Rice Upgrades Hold → Buy
08/12/2019 25.57% Susquehanna → $25 Upgrades Neutral → Positive
07/31/2019 70.77% Raymond James $32 → $34 Maintains Outperform
07/31/2019 Seaport Global Upgrades Sell → Neutral
07/31/2019 40.63% Citigroup $23 → $28 Upgrades Neutral → Buy
07/15/2019 Johnson Rice Downgrades Buy → Hold
04/30/2019 55.7% Citigroup $29 → $31 Maintains Neutral
04/15/2019 75.79% Raymond James $40 → $35 Maintains Outperform
04/15/2019 40.63% Barclays $32 → $28 Maintains Equal-Weight
03/11/2019 65.75% Goldman Sachs → $33 Initiates Coverage On → Neutral
01/10/2019 75.79% Stephens & Co. → $35 Initiates Coverage On → Overweight
01/04/2019 45.66% Citigroup $31 → $29 Maintains Neutral
10/30/2018 141.08% Societe Generale → $48 Upgrades Hold → Buy
10/29/2018 90.86% Credit Suisse $43 → $38 Maintains Neutral
10/29/2018 100.9% Barclays $44 → $40 Maintains Equal-Weight
10/29/2018 126.02% Raymond James $55 → $45 Maintains Outperform
10/29/2018 90.86% Wells Fargo $43 → $38 Maintains Market Perform
10/29/2018 100.9% Citigroup $48 → $40 Maintains Neutral
10/29/2018 Evercore ISI Group Upgrades In-Line → Outperform
10/18/2018 131.04% Jefferies $42 → $46 Maintains Hold

What is the target price for NOV (NOV)?

The latest price target for NOV (NYSE: NOV) was reported by Morgan Stanley on October 17, 2023. The analyst firm set a price target for $25.00 expecting NOV to rise to within 12 months (a possible 25.57% upside). 30 analyst firms have reported ratings in the last year.

What is the most recent analyst rating for NOV (NOV)?

The latest analyst rating for NOV (NYSE: NOV) was provided by Morgan Stanley, and NOV maintained their overweight rating.

When is the next analyst rating going to be posted or updated for NOV (NOV)?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NOV, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NOV was filed on October 17, 2023 so you should expect the next rating to be made available sometime around October 17, 2024.

Is the Analyst Rating NOV (NOV) correct?

While ratings are subjective and will change, the latest NOV (NOV) rating was a maintained with a price target of $24.00 to $25.00. The current price NOV (NOV) is trading at is $19.91, which is out of the analyst's predicted range.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment